Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: A review of the clinical evidence

Clinical Interventions in Aging

Volumn 3, Issue 1, 2008, Pages 1-8

  Garefalakis, Maria ^a   Hickey, Martha ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Androgens; Menopause; Progestins; Testosterone; Therapeutic; Tibolone

Indexed keywords

ANDROGEN; CYPROTERONE ACETATE; DIENOGEST; DROSPIRENONE; DYDROGESTERONE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NANDROLONE; NANDROLONE DERIVATIVE; PLACEBO; POLYCARBOPHIL; PRASTERONE; PROGESTERONE; TESTOSTERONE; TIBOLONE;

ACNE; BREAST CANCER; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE SEXUAL DYSFUNCTION; HIRSUTISM; HOT FLUSH; HUMAN; LIBIDO DISORDER; MENOPAUSAL SYNDROME; MONOTHERAPY; MOOD DISORDER; NIGHT SWEAT; REVIEW; UNSPECIFIED SIDE EFFECT; VAGINAL DRYNESS; VASOMOTOR DISORDER;

AFFECT; ANDROGENS; COGNITION; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; LIBIDO; MENOPAUSE; MIDDLE AGED; NORPREGNENES; PROGESTINS; TESTOSTERONE;

EID: 42449146122     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Albertazzi P, Di Micco R, Zanardi E. 1998. Tibolone: a review. Maturitas, 30:295-305.
2. Anderson GL, Limacher M, Assaf AR, et al. 2004. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA, 291:1701-12
3. Andrews H, Christie B, Colledge N, et al. 2004. Consensus Statement. J R Coll Physicians Edinb, 34 (suppl 13):2-3.
4. Antoine C, Liebens F, Carly B, et al. 2007. Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review. Climacteric, 10:23-6.
5. Antunes CMF, Stolley PD, Rosenstein MB. 1979. Endometrial cancer and estrogen use: report of a large case control study. N Engl J Med, 300:9-13.
6. Archer DF, Hendrix S, Gallagher JC, et al. 2007. Endometrial effects of tibolone. J Clin Endocrinol Metab; 92:911-18.
7. Avis NE, Brambilla D, McKinlay SM, et al. 1994. A longitudinal analysis of the association between menopause and depression. Ann Epidemiol, 4:214-20
8. Baracat ECBI, Giordano MG, Haidar MA, et al. 2002. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone:effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric, 5:60-69.
9. Bachmann GA. 1998. The clinical platform for the 17beta-estradiol vaginal releasing ring. Am J Obstel Gynecol, 178:S257-60.
10. Baker V. 1994. Alternatives to oral oestrogen replacement:transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am, 21:271-97.
11. Barnhart KT, Freeman E, Grisso JA, et al. 1999. The effect of dehydroepi-androsterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab, 84:3896-902.
12. Baulieu EE, Thomas G, LeGrain S, et al. 2000. Dehydroepiandrosterone (DHEA) DHEA sulfate and aging:contribution of the DHEA Age Study to a sociobiomedical issue. Proc Natl Acad Sci USA, 97:4279-84.
13. Beckmann M, Foidart JM, Bundred NJ, et al. 2006. LIBERATE trial: A safety study of tibolone in breast cancer surgery patients - design and baseline date. German Medical Science. Meeting [abstract online] Accessed September 2006. URL: http://www.egms.de/en/meetings/dkk2006/ 06dkk011.shtml.
14. Bell RJ, Donath S, Davison SL, Davis SR. 2006. Endogenous androgen levels and well-being: differences between premenopausal and postmenopausal women. Menopause, 13:65-71.
15. Beresford SAA, Weiss NS, Voigt LF, et al. 1997. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestin therapy in postmenopausal women. Lancet, 349:458-61.
16. Bjarnason K. Cerin A, Lindgren R, Weber T. 1999. Adverse endornetrial effects during long cycle hormone replacement therapy. Maturitas, 32:161-70.
17. Boothby LA, Doering PL, Kipersztok S. 2004. Bioidentical hormone therapy:a review. Menopause, 11:356-67.
18. Braunstein GD. 2002. Androgen insufficiency in wornew:summary of critical issues. Fertil Steril, 77:S94-9.
19. Braunstein GD, Sundwall DA, Katz M, et al. 2000. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women:a randomized, placebo-controlled trial. Arch Intern Med, 165:1582-9
20. Brown JS, Vittinghoff E, Kanaya AM, et al. 2001. Urinary tract infections in postmenopausal women:effect of hormone therapy and risk factors. Obstet Gynecol, 98:1045-52
21. Bruce D, Robinson J, Rymer J. 2004. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. Climacteric, 7:261-6
22. Burkhardt MS, Foster JK, Laws SM, et al. 2004. Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4. J Alzheimers Dis, 6:221-8.
23. Buster JE, Kingsberg SA, Aguirre O, et al. 2005. Testosterone patch for low sexual desire in surgically menopausal women:a randomized trial. Obstet Gynecol, 105:944-52.
24. Bygdeman M, Swahn ML. 1996. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas, 23:259-63.
25. Cameron DR, Braunstein GD. 2004. Androgen replacement therapy in women. Fertil Steril, 82:273-89.
26. Cardozo L, Bachmann G, McClish D et al. 1998. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women:second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol, 92:722-7
27. Carlson MC, Zandi PP, Plassman BL, et al. 2001. Hormone replacement therapy and reduced cognitive decline in older women:the Cache County Study. Neurology, 57:2210-6.
28. Castelo-Branco C, Vicente JJ, Figueras F, et al. 2000. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas, 34:161-8.
29. Colacurci N, Mele P, Costa V, et al. 1998. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol, 80:23 5-8.
30. Davis SR, McCloud P, Strauss BJ, et al. 1995. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas, 21:227-36.
31. Davis SR. 2002. The effects of tibolone on mood and libido. Menopause, 9:162-70.
32. Davis SR, Goldstart R, Papalia MA. 2006. Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone:a randomized, placebo-controlled trial. Menopause, 13:37-45.
33. Dennerstein L, Guthrie JR, Clark M, Lehert P, Henderson VW. 2004. A population-based study of depressed mood in the middle-aged, Australian-born women. Menopause, 11:563-8.
34. Dimitriakis C, Jones RA, Liu A, et al. 2004. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause, 11:531-5
35. Dören M, Ruebig A, Holzgreve W. 2001. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril, 75:554-8.
36. Dow MG, Hart DM, Forrest CA. 1983. Hormonal treatments of sexual unresponsiveness in postmenopausal women:a comparative study. Br J Obstet Gynaecol, 90:361-6.
37. Egarter C, Topcuoglu AM, Vogl S, et al. 2002. Hormone replacement therapy with tibolone:effects on sexual functioning in postmenopausal women. Acta Obstetricia et Gynecologica Scandinavica, 81:649-53.
38. Espeland MA, Rapp SR, Shumaker SA, et al. 2004. Conjugated equine estrogens and global cognitive function in postmenopausal women:Women's Health Initiative Memory Study. JAMA, 291:2959-68.
39. Ginsburg J, Prelevic G. 1995. Tibolone in postmenopausal women with a history of breast carcinoma. J Br Menopause Soc, 1:24-5.
40. Green PK, Weiss NS, McKnight B, et al. 1996. Risk of endometrial cancer following cessation of menopausal hormone use. Cancer Causes Control, 7:575-80
41. Hammar M, Christau S, Nathorst-Böös J, et al. 1998. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol, 105:904-11.
42. Hankinson SE, Eliassen AH. 2007. Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk. J Steroid Biochem Mol Biol, 106:24-30.
43. Henderson BE, Casagrande JT, Pike MC, et al. 1983. The epidemiology of endometrial cancer in young women. Br J Cancer, 47:749-56.
44. Horwitz R, Feinstein AR. 1978. Alternative analytic methods for case control studies of oestrogens and endometrial cancer. N Engl J Med, 299:1089-94.
45. Hoda D, Perez DG, Loprinzi CL. 2003. Hot flashes in breast cancer survivors. Breast J, 9:431-8.
46. Hyder SM, Chiappetta C, Stancel GM. 2001. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer, 92:469-73.
47. Khan SA, Pace JE, Cox ML, et al. 1994. Climacteric symptoms in healthy middle-aged women. Br J Clin Pract, 48:240-2.
48. Kroiss R, Fentiman IS, Helmond FA, et al. 2005. The effect of tibolone in postmenopausal women receiving tamolifen after surgery for breast cancer:a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynaecol, 112:228.
49. Kronenberg F. 1990. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci, 592:52-86; discussion 123-33.
50. Kronenberg F. 1994. Hot flashes: phenomenology, quality of life and search for treatment options. Exp Gerontol, 29:319-36.
51. Laan E, van Lunsen RH. 2001. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric, 4:28-41.
52. Landgren MB, Coelingh Bennink HJT, et al. 2002. Dose-response analysis of effects of tibolone on climacteric symptoms. Br J Obstel Gynaecol, 109:1109-14.
53. LeBlanc ES, Janowsky J, Chan BKS, et al. 2001. HRT and cognition:systematic review and meta-analysis. N Engl J Med, 285:1489-99.
54. Leonetti HB, Longo S, Anasti JN. 1999. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol, 94:225-8.
55. Lobo RA, Rosen RC, Yang HM, et al. 2003. Comparative effects of oral esterified estrogens with and without methyl testosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril, 79:1341-52.
56. Lokkegaard E, Pedersen AT, Laursen P, et al. 2002. The influence of hormone replacement therapy on the aging-related change in cognitive performance: analysis based on a Danish cohort study. Maturitas, 42:209-18.
57. Loprinzi CL, Michalak JC, Quella SK. 1994. Megestrol acetate for the prevention of hot flashes. N Engl J Med, 331:347-52.
58. Loprinzi, et al. 2006. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol, 24:1409-14.
59. MacLennan AH, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2002; 1: CD002978.
60. McBee WL, Dailey ME, Dugan E, et al. 1997. Hormone replacement therapy and other potential treatments for dementias. Endocrinol Metab Clin North Am, 26:329-45.
61. Million Women Study Collaborators. 2003. Breast cancer and hormone-replacement therapy in the Million Woman Study. Lancet, 362:419-27
62. Million Women Study Collaborators. 2005. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet, 365:1543-51.
63. Modelska K, Cummings S. 2002. Tibolone for Postmenopausal Women: Systematic Review of Randomized Trials. J Clin Endocrinol Metab, 87:16-23
64. Mulnard RA, Cotman CW, Kawas C, et al. 2000. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease:a randomized controlled trial: Alzheimer's Disease Cooperative Study. JAMA, 283:1007-15.
65. Nachtigall LE. 1994. Comparative study:replens versus local estrogen in menopausal women. Fertil Steril, 61:178-80.
66. Naftolin F, Schneider H, Sturdee D. 2004. Guidelines for the hormone treatment of women in the menopausal transition and beyond:position statement by the executive committee of the International Menopause Society. Climacteric, 7:333-37.
67. Natale V, Albertazzi P, Zini M, et al. 2001. Exploration of cyclical changes in memory and mood in post menopause women taking sequential combined oestrogen and progestin preparations. BJOG, 108:286-90.
68. Nathorst-Böös J, Hammar M. 1997. Effect on sexual life-a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas, 26:15-20
69. Paganini-Hill RR, Henderson BE. 1989. Endometrial cancer and patterns of use of oestrogen replacement therapy:a cohort study. Br J Cancer, 59:445-7.
70. Panjari M, Davis SR. 2007. DHEA therapy for women:effect on sexual function and wellbeing. Hum Reprod Update, 13:239-48
71. Pasqualini JR, Chetrite G, Blacker C, et al. 1996. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab, 81:1460-4.
72. Prestwood KM, Kenny AM, Kleppinger A, et al. 2003. Ultralowdose micronized 17beta-estradiol and bone density and bone metabolism in older women:a randomized controlled trial. JAMA, 290:1042-8.
73. Pukkala E, Tulenheimo-Silfvast A, Leminem A. 2001. Incidence of cancer among women using long versus monthly cycle HRT Finland 1994-1997. Cancer Causes Control, 12:111-15.
74. Quella SK, Loprinzi CL, Sloan JA, et al. 1998. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer, 82:1784-8.
75. Riphagen F. 2000. Intrauterine application of progestins in hormone replacement therapy. Climacteric, 3:199-211.
76. Ross LA, Adler EM, Cawood EHH, et al. 1999. Psychological effects of hormone replacement therapy:a comparison of tibolone and a sequential estrogen therapy. J Psychosom Obstet Gynaecol, 20:88-96.
77. Rossouw JE, Anderson GL, Prentice RL, et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women:Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288:321-33.
78. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Writing Group for the Consensus Panel. 2004. Advice to medical practitioners regarding the use of postmenopausal hormone therapy. [online] Accessed September 2006 URL: http://www.ranzcog.edu.au/ media/pdfs/HTAdviceStatement12th%20Aug.pdf.
79. Sarrel P, Dobay B, Wiita B. 1998. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen only therapy:sexual behaviour and neuroendocrine responses. J Reprod Med, 43:847-56.
80. Schiff I, Tulchinsky D, Cramer D, et al. 1980. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA, 244:1443-5.
81. Schindler A. 2003. Differential effects of progestins on hemostasis. Maturitas; 46(Suppl 1):S31-7.
82. Schindler AE, Canpagnoli C, Druckmann R, et al. 2003. Classification and pharmacology of progestins. Maturitas, 46(Suppl 1):S7-S 16.
83. Sherwin BB, Gelfand MM, Brender W. 1985. Androgen enhances sexual motivation in females:a prospective crossover study of sex steroid administration in the surgical menopause. Psychosom Med, 47:33951.
84. Sherwin B. 1991. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab, 72:336-43.
85. Shifren JL. 2002. Androgen deficiency in the oophorectornized woman. Fertil Steril, 77(Suppl 4):S60-2
86. Shumaker SA, Legault C, Rapp SR, et al. 2003. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women:a randomized controlled trial. JAMA, 289:2651-62.
87. Shumaker SA, Legault C, Kuller L, et al. 2004. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women:Women's Health Initiative Memory Study. JAMA, 291:2947-58.
88. Simon JA, Klaiber E, Wiita B, et al. 1996. Double-blind comparison of two doses of estrogen and estrogen-androgen therapy in naturally postmenopausal women:neuroendocrine, psychological, and psychosomatic effects. Fertil Steril, 66: S71.
89. Simpson E, Rubin G, Clyne C, et al. 2000. The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab, 11: 184-8.
90. Slowinska-Srzednicka J, Zgliczynski S, Jeske W, et al. 1992. Transdermal 17beta-estradiol combined with oral progestin increases plasma levels of insulin-like growth factor-I in postmenopausal women. J Endocrinol Invest, 15:533-8.
91. Somboonporn W, Davis S, Seif MW, et al. 2005. Testosterone for peri- and postmenopausal women. Cochrane Database of Systematic Reviews. Issue 4. Art. No.:CD004509. DOI:10.1002/14651858.CD004509.pub2.
92. The North American Menopause Society. 2005. The role of testosterone therapy in postmenopausal womemposition. statement of The North American Menopause Society. Menopause, 12:497-511.
93. Traish A, Guay AT, Spark RF. 2007. Testosterone Therapy in Women Study Group. Are the Endocrine Society's Clinical Practice Guidelines on Androgen Therapy in Women misguided? A commentary. J Sex Med, 4:1223-34.
94. Valdivia I, Campodonico I, Tapia A, et al. 2004. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril, 81:617-23.
95. Warren R. 2004. Hormones and mammographic breast density. Maturitas, 49:67-78.
96. Watts NB, Notelovitz M, Timmons MC, et al. 1995. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol, 85:529-37,
97. Weiderpass E, Adami HO, Baron JA, et al. 1999. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst, 91:1131-7.
98. Wells M, Sturdee DW, Barlow DH, et al. 2002. Effect on endometrium of long term treatment with continuous combined estrogen/progestin replacement therapy; follow up study. BMJ, 325:239-42.
99. Wierman ME, Basson R, Davis SR, et al. 2006. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab, 91:3697-710.
100. WHO. 1966. Technical report series:menopause. 7:236-42.
101. Wisniewski A, Nguyen TT, Dobs AS. 2002. Evaluation of high-dose estrogen and high-dose estrogen plus methyltestosterone treatment on cognitive task performance in postmenopausal women. Horm Res, 58:150-5.
102. Wren BG, Champion SM, Willetts Y, et al. 2003. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause, 10:13-8.